1-5 of 5
Tu My To
Close
Sort by
Journal Articles

Healthcare Resource Utilization and Costs Associated with Obinutuzumab Plus Bendamustine Versus Rituximab Plus Bendamustine for First-Line Treatment of Follicular Lymphoma

Tu My To, Jamie T. Ta, Arpamas Seetasith, Rongrong Wang, Dominic Lai, Sheila Shapouri
Journal: Blood
Blood (2021) 138 (Supplement 1): 3004.
https://doi.org/10.1182/blood-2021-145607
Published: 2021
Journal Articles

Real-World Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First-Line (1L) Therapy in the United States (US)

Anthony R. Mato, Arliene Ravelo, Tu My To, Robert Schuldt, Juliana M.L. Biondo
Journal: Blood
Blood (2021) 138 (Supplement 1): 4086.
https://doi.org/10.1182/blood-2021-148472
Published: 2021
Journal Articles

Healthcare Resource Utilization and Costs of Patients with Relapsed/Refractory Follicular Lymphoma Receiving 3 or More Lines of Therapy

Matthew J. Matasar, Sheila Shapouri, Jamie T. Ta, Tu My To, Mei Wu, Rongrong Wang
Journal: Blood
Blood (2021) 138 (Supplement 1): 1923.
https://doi.org/10.1182/blood-2021-145407
Published: 2021
Journal Articles

Health Resource Utilization and Costs Associated with the Use of Obinutuzumab-Based Regimens Are Similar to Rituximab-Based Regimens for the First-Line Treatment of Follicular Lymphoma

Tu My To, PhD, Keith L. Dawson, DNP, MS, Anthony S Masaquel, PhD MPH, Arpamas Seetasith, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4721.
https://doi.org/10.1182/blood-2019-123408
Published: 2019
Journal Articles

Patterns of Ibrutinib Use, Discontinuation, and Hospitalization Among Patients with Chronic Lymphocytic Leukemia (CLL) in a US Healthcare Claims Database

Tu My To, PhD MPH, Wei-Shi Yeh, PhD MS, Juliana Biondo, Anthony S Masaquel, PhD MPH
Journal: Blood
Blood (2018) 132 (Supplement 1): 5909.
https://doi.org/10.1182/blood-2018-99-112679
Published: 2018